Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

1.

Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.

Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA.

Oncogene. 2003 Oct 20;22(47):7316-39. Review.

PMID:
14576841
[PubMed - indexed for MEDLINE]
2.

Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.

Katzenellenbogen BS, Choi I, Delage-Mourroux R, Ediger TR, Martini PG, Montano M, Sun J, Weis K, Katzenellenbogen JA.

J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):279-85. Review.

PMID:
11162936
[PubMed - indexed for MEDLINE]
3.

Molecular and pharmacological aspects of antiestrogen resistance.

Clarke R, Skaar TC, Bouker KB, Davis N, Lee YR, Welch JN, Leonessa F.

J Steroid Biochem Mol Biol. 2001 Jan-Mar;76(1-5):71-84. Review.

PMID:
11384865
[PubMed - indexed for MEDLINE]
4.

Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.

Kurokawa H, Arteaga CL.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4436s-4442s; discussion 4411s-4412s. Review.

PMID:
11916237
[PubMed - indexed for MEDLINE]
5.

[Hormone resistance and its modulation in breast cancer].

Kahán Z, Thurzó L.

Orv Hetil. 2005 Apr 17;146(16):731-7. Review. Hungarian.

PMID:
15889669
[PubMed - indexed for MEDLINE]
6.

The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.

Howell SJ, Johnston SR, Howell A.

Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):47-66. Review.

PMID:
14687597
[PubMed - indexed for MEDLINE]
7.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
[PubMed - indexed for MEDLINE]
8.

Therapeutic targeting in the estrogen receptor hormonal pathway.

Katzenellenbogen BS, Frasor J.

Semin Oncol. 2004 Feb;31(1 Suppl 3):28-38. Review.

PMID:
15052541
[PubMed - indexed for MEDLINE]
9.

William L. McGuire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer.

Katzenellenbogen BS, Montano MM, Ekena K, Herman ME, McInerney EM.

Breast Cancer Res Treat. 1997 May;44(1):23-38. Review.

PMID:
9164675
[PubMed - indexed for MEDLINE]
10.

Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.

Lykkesfeldt AE.

Acta Oncol. 1996;35 Suppl 5:9-14. Review.

PMID:
9142958
[PubMed - indexed for MEDLINE]
11.

Antiestrogens--tamoxifen, SERMs and beyond.

Dhingra K.

Invest New Drugs. 1999;17(3):285-311. Review.

PMID:
10665480
[PubMed - indexed for MEDLINE]
12.

Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.

Osborne CK, Shou J, Massarweh S, Schiff R.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):865s-70s. Review.

PMID:
15701879
[PubMed - indexed for MEDLINE]
Free Article
13.

Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer.

Lee AV, Cui X, Oesterreich S.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4429s-4435s; discussion 4411s-4412s. Review.

PMID:
11916236
[PubMed - indexed for MEDLINE]
14.

Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.

Girault I, Bièche I, Lidereau R.

Maturitas. 2006 Jul 20;54(4):342-51. Epub 2006 Jul 5. Review.

PMID:
16822624
[PubMed - indexed for MEDLINE]
15.

A 2009 update on the treatment of patients with hormone receptor-positive breast cancer.

Cleator SJ, Ahamed E, Coombes RC, Palmieri C.

Clin Breast Cancer. 2009 Jun;9 Suppl 1:S6-S17. doi: 10.3816/CBC.2009.s.001. Review.

PMID:
19561006
[PubMed - indexed for MEDLINE]
16.

Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer.

Osborne CK, Schiff R.

Breast. 2003 Dec;12(6):362-7. Review.

PMID:
14659106
[PubMed - indexed for MEDLINE]
17.

Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.

Lewis JS, Jordan VC.

Mutat Res. 2005 Dec 11;591(1-2):247-63. Epub 2005 Aug 3. Review.

PMID:
16083919
[PubMed - indexed for MEDLINE]
18.

Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.

Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK.

Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:10-20. Review.

PMID:
16273359
[PubMed - indexed for MEDLINE]
19.

Antiestrogen resistance in ER positive breast cancer cells.

Paik S, Hartmann DP, Dickson RB, Lippman ME.

Breast Cancer Res Treat. 1994;31(2-3):301-7. Review.

PMID:
7881107
[PubMed - indexed for MEDLINE]
20.

[Mechanism of acquired antiestrogen resistance and its management in breast cancer].

Iino Y, Maemura M, Morishita Y.

Nihon Rinsho. 1997 May;55(5):1149-54. Review. Japanese.

PMID:
9155167
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk